15.76

5.91% 0.88

Pre-market: 15.59 -0.17 -1.08%

Biohaven Ltd (BHVN)

Overview News Price History Option Chain Financials Why BHVN Down? Discussions Forecast

Biohaven Ltd stock is traded at $15.76, with a volume of 4.74M. It is up +5.91% in the last 24 hours and up +37.88% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Previous Close:

$14.88

Open:

$14.95

24h Volume:

4.74M

Relative Volume:

1.70

Market Cap:

$2.37B

Revenue:

Net Income/Loss:

$-647.68M

P/E Ratio:

-2.7795

EPS:

-5.67

Net Cash Flow:

$-594.49M

1W Performance:

+5.35%

1M Performance:

+37.88%

6M Performance:

+39.59%

1Y Performance:

+12.89%

1-Day Range:

$14.59

$15.80

1-Week Range:

$14.05

$16.74

52-Week Range:

$7.48

$18.57

Biohaven Ltd Stock (BHVN) Company Profile

Name

Biohaven Ltd

Sector

Healthcare (1092)

Industry

Biotechnology (615)

Phone

203-404-0410

Address

215 CHURCH STREET, NEW HAVEN, CT

Employee

274

Twitter

@biohavenpharma

Next Earnings Date

2026-08-10

Latest SEC Filings

BHVN's Discussions on Twitter

Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BHVN Biohaven Ltd	15.76	2.24B	0	-647.68M	-594.49M	-5.67
VRTX Vertex Pharmaceuticals Inc	498.01	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	624.72	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	909.50	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.67	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	187.51	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	Canaccord Genuity	Buy
Feb-06-26	Initiated	Goldman	Buy
Jan-21-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Dec-03-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-26-25	Downgrade	UBS	Buy → Neutral
Nov-06-25	Downgrade	Bernstein	Outperform → Mkt Perform
Nov-05-25	Downgrade	BofA Securities	Buy → Neutral
Sep-17-25	Initiated	Citigroup	Buy
Sep-03-25	Initiated	Raymond James	Strong Buy
May-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-11-25	Initiated	Deutsche Bank	Buy
Sep-16-24	Initiated	Jefferies	Buy
Sep-04-24	Initiated	Bernstein	Outperform
Jul-24-24	Initiated	Morgan Stanley	Overweight
Feb-16-24	Initiated	RBC Capital Mkts	Outperform
Feb-06-24	Initiated	UBS	Buy
Dec-22-23	Initiated	H.C. Wainwright	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Jan-24-23	Initiated	SVB Securities	Outperform
Jan-04-23	Initiated	JP Morgan	Overweight
Dec-02-22	Initiated	BTIG Research	Buy
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-12-22	Initiated	Piper Sandler	Overweight
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-10-21	Downgrade	UBS	Buy → Neutral
Aug-03-21	Reiterated	Canaccord Genuity	Buy
Mar-11-21	Initiated	UBS	Buy
Dec-15-20	Initiated	H.C. Wainwright	Buy
Apr-17-20	Initiated	Cowen	Outperform
Feb-10-20	Downgrade	Oppenheimer	Outperform → Perform
Feb-06-20	Initiated	Mizuho	Buy
Nov-22-19	Initiated	Wedbush	Outperform
Jun-25-19	Reiterated	Canaccord Genuity	Buy
May-06-19	Initiated	Goldman	Buy
Apr-09-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-04-19	Reiterated	Needham	Buy
Jul-03-18	Reiterated	Needham	Buy
Jul-02-18	Reiterated	Needham	Buy
Apr-05-18	Downgrade	Barclays	Overweight → Equal Weight
Feb-22-18	Reiterated	Canaccord Genuity	Buy
Dec-15-17	Initiated	Canaccord Genuity	Buy
Oct-03-17	Reiterated	Needham	Buy

View All

Biohaven Ltd Stock (BHVN) Latest News

Jul 01, 2026

Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)? - simplywall.st

Jul 01, 2026

Jun 30, 2026

Biohaven completes enrollment in opakalim epilepsy trial - Investing.com

Jun 30, 2026

Biohaven completes enrollment in opakalim epilepsy trial By Investing.com - Investing.com Canada

Jun 30, 2026

Biohaven completes enrollment in focal epilepsy drug trial - StreetInsider

Jun 30, 2026

Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment - Stock Titan

Jun 30, 2026

Jun 29, 2026

Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA - Moomoo

Jun 29, 2026

BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - marketscreener.com

Jun 29, 2026

Biohaven Doses First Patient in Phase 3 Trial of BHV-1300 for Graves' Disease - marketscreener.com

Jun 29, 2026

Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga

Jun 29, 2026

Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - Moomoo

Jun 29, 2026

BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target - Moomoo

Jun 29, 2026

BofA downgrades Biohaven stock on epilepsy drug concerns By Investing.com - Investing.com Australia

Jun 29, 2026

BofA downgrades Biohaven stock on epilepsy drug concerns - Investing.com

Jun 29, 2026

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease - PR Newswire

Jun 29, 2026

Jun 27, 2026

BHVN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Jun 27, 2026

Jun 26, 2026